Checkpoint Inhibitor Refractory Cancer Market to Grow with a CAGR of 8.49% through 2028
Growing incidences of refractory cancers are
expected to drive the Global Checkpoint Inhibitor Refractory Cancer Market
growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Checkpoint Inhibitor Refractory Cancer Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2028”, the Global Checkpoint Inhibitor Refractory Cancer Market stood at USD
32.49 Billion in 2022 and is anticipated to grow with a CAGR of 8.49% through
2028. The growing use of combination therapies, involving the use of multiple
cancer treatments in combination to improve treatment outcomes is the important
reason for the considerable share of the segment. PD-1 inhibitors are often
used in combination with other immunotherapies, such as CTLA-4 inhibitors and
immune checkpoint agonists, to enhance their effectiveness. The Hodgkin lymphoma segment is expected
to grow with a higher CAGR in the checkpoint inhibitor refractory cancer market
during the forecast period. The increasing incidences of Hodgkin lymphoma are
the major driving factor for the fast growth of the anesthesia segment. For
instance, according to Cancer.Net, in 2020, 3,087 people were diagnosed with
Hodgkin lymphoma in 2020 globally.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Checkpoint Inhibitor Refractory Cancer Market”
The Global Checkpoint
Inhibitor Refractory Cancer Market is segmented into Device, End User and
company.
Based on the
Type, the PD-1 Inhibitor segment is anticipated to witness substantial market
growth throughout the forecast period. The growth of the Global Checkpoint
Inhibitor Refractory Cancer Market is strongly influenced by the prominence of
PD-1 inhibitors. PD-1 inhibitors, a class of immunotherapies, play a pivotal
role in unleashing the body's immune response against cancer cells by blocking
the programmed cell death protein 1 pathway. As a cornerstone of checkpoint
inhibitor therapy, PD-1 inhibitors have demonstrated significant efficacy in
various cancers. Their widespread adoption stems from their ability to overcome
resistance mechanisms and address checkpoint inhibitor refractory cases. PD-1
inhibitors exhibit versatility, showing promise across diverse tumor types,
thereby expanding their market applicability. As a result, pharmaceutical
companies are investing heavily in the development and clinical validation of
PD-1 inhibitors, both as monotherapies and in combination with other agents.
The market's growth is driven by the expanding repertoire of PD-1 inhibitors,
supported by robust clinical evidence and regulatory approvals.
Based on the
Application segment, the Hodgkin Lymphoma segment has been the dominant force
in the market. The growth of the Global Checkpoint Inhibitor Refractory Cancer
Market is set to be significantly driven by the unique position of Hodgkin
Lymphoma (HL) within this therapeutic landscape. Hodgkin Lymphoma,
characterized by the presence of Reed-Sternberg cells, has demonstrated a
notable responsiveness to checkpoint inhibitors, particularly PD-1 inhibitors
like pembrolizumab and nivolumab. As a flagship indication for checkpoint
inhibitor success, the positive clinical outcomes in refractory or relapsed
Hodgkin Lymphoma cases have underscored the potential of these immunotherapies.
The remarkable efficacy in HL has led to expanded regulatory approvals and an
increasing acceptance of checkpoint inhibitors as a standard treatment option.
The success in HL not only establishes checkpoint inhibitors as a viable
therapeutic approach but also serves as a catalyst for broader applications
across various cancers. This has attracted substantial investments from
pharmaceutical companies and heightened interest from clinicians, driving
research and development efforts.
Major
companies operating in Global Checkpoint Inhibitor Refractory Cancer
Market are:
- Bristol-Myers
Squibb Company.
- AstraZeneca plc.
- Merck KGaA
- F. Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals Inc
- Pfizer Inc
- Janssen Global Services, LLC
- 4SC AG
- Mirati Therapeutics, Inc.
- Ascentage Pharma
Download Free Sample Report
Customers can
also request 10% free customization on this report
“The Global
Checkpoint Inhibitor Refractory Cancer Market is driven by a confluence of
factors shaping its trajectory. Technological advancements in immunotherapy,
particularly checkpoint inhibitors, have revolutionized cancer treatment. The
rising incidence of various cancers and the increasing understanding of immune
escape mechanisms fuel the demand for novel therapeutic interventions.
Additionally, collaborative research efforts and robust investment in oncology
research contribute to the market's expansion. The quest for personalized
medicine and the identification of biomarkers for patient stratification
further propel the development of innovative checkpoint inhibitor refractory
cancer therapies. Moreover, the evolving regulatory landscape and expedited approval
processes enhance market dynamics, fostering a competitive environment. These
drivers collectively underscore the market's growth, promising a transformative
impact on the landscape of cancer care.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Checkpoint
Inhibitor Refractory Cancer Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Type (PD-1 Inhibitor, PD-L1
Inhibitor, Others), By Application (Lung Cancer, Bladder Cancer, Melanoma,
Hodgkin Lymphoma, Others), By Region, By Competition”,
has evaluated the future growth potential of Global Checkpoint Inhibitor
Refractory Cancer Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Checkpoint Inhibitor
Refractory Cancer Market.
Contact
TechSci Research
LLC
420 Lexington
Avenue, Suite 300,
New York, United
States- 10170
Tel:
+1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com